logo-loader
viewSynthis

Synthis looking at a different and unique way of treating oncology patients

Dori Karyat, Founder and CEO and founder, Synthis is an early stage, New York-based biotech company, sat down with Christine Corrado at the BioCeo conference In New York, to share news about their novel immuno-oncology therapeutic way of treating metastatic melanoma patients. Karyat talks about how the company started and where they are in their development. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: NexTech AR Resources signs new deal for augmented reality in...

NexTech AR Solutions (CSE:NTAR-OTCQB: NEXCF) CEO Evan Gappelberg joined Steve Darling from Proactive Vancouver with news the company has signed another deal with a company in the arms sector. This deal is with Steyr Arms, a world-renowned firearms manufacturer.  Gappelberg says NexTech...

31 minutes ago

2 min read